Current limitations and future opportunities for epigenetic therapies.
about
Comprehensive histone phosphorylation analysis and identification of Pf14-3-3 protein as a histone H3 phosphorylation reader in malaria parasitesAdvancements in the delivery of epigenetic drugsSmall-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparumEfficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals.Perspectives on natural product epigenetic modulators in chemical biology and medicine.Alterations of DNA methylome in human bladder cancer.Epigenetics of human melanoma: promises and challenges.The anticancer effect of chaetocin is enhanced by inhibition of autophagy.Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinomaChaetocin is a nonspecific inhibitor of histone lysine methyltransferases.Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors.Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A.Interview with Future Medicinal Chemistry's US Senior Editor, Iwao Ojima. Interview by Issac Bruce.
P2860
Q27973893-9A1E6084-6D88-400B-BD03-2A1349B903CBQ28088478-1231318B-1AD9-4105-9415-6B0E22141978Q34421556-ACD273DD-0633-496A-AB8C-45EC6D06AA93Q36609590-50273595-C604-4EEC-9A1D-400635C4BFA3Q37374917-D1C00662-B1C4-48C6-B2C7-0CA308B255B2Q37420213-516DAC34-2A22-4DB0-A439-D3D1770EE391Q37719054-812F7AE6-359F-47A3-9AE1-137E04558DB1Q38080414-85A48054-5FC2-47EF-9796-AF4C60ACAD60Q38131409-C3FCDD56-94A1-4472-ADC3-E37A9AD86AF2Q38217482-2C208B31-4806-4BA4-8CE5-6C5E9A580A9BQ38793061-EEBB923B-71ED-436A-8E1D-F39D1CF10FBFQ38793579-EACA3EE5-04E0-4DE9-A24D-F8D1979C42D7Q42712897-EA30076E-7AE0-4B47-AEA8-25A9B7E456D9Q43202230-8026E783-B851-4D8D-8738-51A262EB2E9FQ43526647-BF55F2AC-EB1C-4D88-ADE2-9359E61BA398Q48409114-61108092-2486-4DD7-A53E-1D7F7420378B
P2860
Current limitations and future opportunities for epigenetic therapies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Current limitations and future opportunities for epigenetic therapies.
@ast
Current limitations and future opportunities for epigenetic therapies.
@en
Current limitations and future opportunities for epigenetic therapies.
@nl
type
label
Current limitations and future opportunities for epigenetic therapies.
@ast
Current limitations and future opportunities for epigenetic therapies.
@en
Current limitations and future opportunities for epigenetic therapies.
@nl
prefLabel
Current limitations and future opportunities for epigenetic therapies.
@ast
Current limitations and future opportunities for epigenetic therapies.
@en
Current limitations and future opportunities for epigenetic therapies.
@nl
P2093
P2860
P356
P1476
Current limitations and future opportunities for epigenetic therapies
@en
P2093
F Cherblanc
N Chapman-Rothe
P2860
P304
P356
10.4155/FMC.12.7
P577
2012-03-01T00:00:00Z